^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

GNRHR expression

i
Other names: GNRHR, Gonadotropin Releasing Hormone Receptor, Gonadotropin-Releasing Hormone Receptor, GnRH Receptor, GnRH-R, LHRHR, GRHR, Gonadotropin-Releasing Hormone (Type 1) Receptor 1, Leutinizing Hormone Releasing Horomone Receptor, Leutinizing-Releasing Hormone Receptor, Type I GnRH Receptor, Luliberin Receptor, GNRHR1, GNRHR, LRHR, HH7
Entrez ID:
1year
AXL receptor tyrosine kinase modulates gonadotropin-releasing hormone receptor signaling. (PubMed, Cell Commun Signal)
Altogether, these data describe a novel role for AXL as a modulator of GnRH receptor signaling. Video Abstract.
Journal
|
AXL (AXL Receptor Tyrosine Kinase) • GAS6 (Growth arrest specific 6) • MMP9 (Matrix metallopeptidase 9)
|
GNRHR expression
over1year
Conventional and new proposals of GnRH therapy for ovarian, breast, and prostatic cancers. (PubMed, Front Endocrinol (Lausanne))
Another recent approach based on this knowledge was the use of GnRH peptides for developing specific targeted therapies, improving the delivery and accumulation of drugs in tumoral cells, and decreasing most side effects of current treatments. In this review, we discuss the conventional uses of GnRH analogs, together with the recent advances in GnRH-based drug delivery for ovarian, breast, and prostatic cancer cells.
Review • Journal
|
GNRHR (Gonadotropin Releasing Hormone Receptor)
|
GNRHR expression • GNRH1 expression
over2years
Gonadotropin-releasing hormone receptor inhibits triple-negative breast cancer proliferation and metastasis. (PubMed, J Int Med Res)
GnRHR inhibits TNBC proliferation and metastasis, suggesting it could be targeted for TNBC treatment.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
GNRHR expression • GNRH1 expression
|
leuprolide acetate for depot suspension
over3years
New drug delivery strategies targeting GnRH receptor in breast and other cancers. (PubMed, Endocr Relat Cancer)
Some promising findings from these studies indicate that GnRH receptor targeting is a potential strategy to efficiently guide anticancer therapeutics, diagnostic agents, and nucleic acids directly to cancer cells. Lastly, some limitations of the current research and suggestions for more successful outcomes in clinical trials of these delivery systems are highlighted.
Review • Journal
|
GNRHR (Gonadotropin Releasing Hormone Receptor)
|
GNRHR expression
over3years
Development of novel GnRH and Tat based luminescent probes with enhanced cellular uptake and bioimaging profile. (PubMed, Dalton Trans)
Besides the selective targeting that the specific conjugate could offer, we also recorded high internalization levels in T24 bladder cancer cells. The ruthenium(ii) polypyridyl peptide-based conjugates we developed is an intriguing approach that offers targeted cell imaging in the Near Infrared region, and simultaneously paves the way for further advancements in the dynamic studies on cellular imaging.
Journal
|
GNRHR (Gonadotropin Releasing Hormone Receptor)
|
GNRHR expression • GNRH1 expression
over3years
Dissecting the Hormonal Signaling Landscape in Castration-Resistant Prostate Cancer. (PubMed, Cells)
This antitumor activity is mainly mediated by the GnRH-R-associated Gαi/cAMP signaling pathway. In this review, we dissect the molecular mechanisms underlying the role of the androgen/AR and GnRH/GnRH-R axes in CRPC progression and the possible therapeutic implications.
Review • Journal
|
AR (Androgen receptor)
|
AR mutation • AR amplification • GNRHR expression